{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T09:07:32Z","timestamp":1773047252380,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T00:00:00Z","timestamp":1715990400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001219","name":"Lymphoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001219","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021045","name":"Massachusetts Department of Public Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Neoplasia"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.bneo.2024.100019","type":"journal-article","created":{"date-parts":[[2024,5,20]],"date-time":"2024-05-20T06:29:28Z","timestamp":1716186568000},"page":"100019","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma"],"prefix":"10.1016","volume":"1","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4964-167X","authenticated-orcid":false,"given":"Christopher S.","family":"Strouse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-5758-2804","authenticated-orcid":false,"given":"Vanessa E.","family":"Siebert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bradley T.","family":"Loeffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8802-7686","authenticated-orcid":false,"given":"Bradley D.","family":"McDowell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1250-1710","authenticated-orcid":false,"given":"Brian J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5084-0698","authenticated-orcid":false,"given":"Brian K.","family":"Link","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bneo.2024.100019_bib1","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/ajh.23708","article-title":"The impact of race, age, and sex in follicular lymphoma: a comprehensive SEER analysis across consecutive treatment eras","volume":"89","author":"Nabhan","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bneo.2024.100019_bib2","doi-asserted-by":"crossref","first-page":"1416","DOI":"10.1038\/s41375-022-01535-y","article-title":"Causes of death of patients with follicular lymphoma in the Netherlands by stage and age groups: a population-based study in the pre- and post-rituximab era","volume":"36","author":"Dinnessen","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.bneo.2024.100019_bib3","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/S0140-6736(03)14110-4","article-title":"Long-term effect of a watch and wait policy versus immediate systemic treatment for asymptomatic advanced-stage non-Hodgkin lymphoma: a randomised controlled trial","volume":"362","author":"Ardeshna","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.bneo.2024.100019_bib4","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1200\/JCO.1997.15.3.1110","article-title":"Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte","volume":"15","author":"Brice","year":"1997","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100019_bib5","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1200\/JCO.18.00400","article-title":"Cause of death in follicular lymphoma in the first decade of the rituximab era: a pooled analysis of French and US Cohorts","volume":"37","author":"Sarkozy","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100019_bib6","first-page":"148","article-title":"Treatment patterns and health care costs in commercially insured patients with follicular lymphoma","volume":"7","author":"Fowler","year":"2020","journal-title":"J\u00a0Health Econ Outcomes Res"},{"key":"10.1016\/j.bneo.2024.100019_bib7","doi-asserted-by":"crossref","first-page":"766","DOI":"10.3109\/10428194.2015.1099647","article-title":"Optimal use of bendamustine in hematologic disorders: treatment recommendations from an international consensus panel - an update","volume":"57","author":"Cheson","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bneo.2024.100019_bib8","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.clml.2014.07.015","article-title":"A\u00a0Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board","volume":"15","author":"Kuruvilla","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bneo.2024.100019_bib9","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1200\/JCO.2017.76.8960","article-title":"Immunochemotherapy with obinutuzumab or rituximab for previously untreated follicular lymphoma in the GALLIUM Study: influence of chemotherapy on efficacy and safety","volume":"36","author":"Hiddemann","year":"2018","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bneo.2024.100019_bib10","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/cid\/ciy458","article-title":"Increased risk of infectious complications in older patients with indolent non-Hodgkin lymphoma exposed to bendamustine","volume":"68","author":"Fung","year":"2019","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.bneo.2024.100019_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/hon.2871","article-title":"Reduction of cycles of bendamustine plus rituximab therapy in the cases with good response for indolent B-cell lymphomas","volume":"39","author":"Takezaki","year":"2021","journal-title":"Hematol Oncol"},{"key":"10.1016\/j.bneo.2024.100019_bib14","doi-asserted-by":"crossref","first-page":"2944","DOI":"10.1182\/blood-2013-11-531327","article-title":"Randomized trial of bendamustine-rituximab or R-CHOP\/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study","volume":"123","author":"Flinn","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bneo.2024.100019_bib15","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.bneo.2024.100019_bib16","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.3109\/10428194.2014.994206","article-title":"Relationships between chemotherapy, chemotherapy dose intensity and outcomes of follicular lymphoma in the immunochemotherapy era: a report from the University of Iowa\/Mayo Clinic Lymphoma Specialized Program of Research Excellence Molecular Epidemiology","volume":"56","author":"Wudhikarn","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.bneo.2024.100019_bib17","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1002\/cncr.28350","article-title":"Patterns of delivery of chemoimmunotherapy to patients with follicular lymphoma in the United States: results of the National LymphoCare Study","volume":"119","author":"Martin","year":"2013","journal-title":"Cancer"},{"key":"10.1016\/j.bneo.2024.100019_bib18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1158\/1078-0432.CCR-22-1654","article-title":"Monitoring of circulating tumor DNA predicts response to treatment and early progression in follicular lymphoma: results of a Prospective Pilot Study","volume":"29","author":"Fern\u00e1ndez-Miranda","year":"2023","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bneo.2024.100019_bib19","doi-asserted-by":"crossref","first-page":"e826","DOI":"10.1097\/HS9.0000000000000826","article-title":"Interim positron emission tomography during frontline chemoimmunotherapy for follicular lymphoma","volume":"7","author":"Merryman","year":"2023","journal-title":"Hemasphere"}],"container-title":["Blood Neoplasia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000190?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950328024000190?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T20:56:31Z","timestamp":1762894591000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950328024000190"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":17,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S2950328024000190"],"URL":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100019","relation":{},"ISSN":["2950-3280"],"issn-type":[{"value":"2950-3280","type":"print"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal number of cycles of bendamustine as initial chemoimmunotherapy for older patients with follicular lymphoma","name":"articletitle","label":"Article Title"},{"value":"Blood Neoplasia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bneo.2024.100019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100019"}}